Qilu Pharmaceutical

Jinan, China

Qilu Pharmaceutical Co., Ltd. is a leading, vertically integrated pharmaceutical company based in China, specializing in the development, manufacturing, and marketing of finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs). With a global presence, they are dedicated to providing high-quality and trustworthy medicines across diverse therapeutic areas.

Shareable draft

Check out Qilu Pharmaceutical on @MedStartr Today Qilu Pharmaceutical Co., Ltd. is a leading, vertically integrated pharmaceutical company based in China, specializing in the development, manufacturing, and marketing of finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs). With a global presence, they are dedicated to providing high-quality and trustworthy medicines across diverse therapeutic areas. #CerebrovascularCardiovascularDiseases #AntiInfections #PsychologicalNeurologicalSystems #RespiratorySystem #OphthalmologicalDiseases #NervousSystemDiseases #EndocrinologyAndMetabolicDisease #HemicAndLymphDiseases #MentalBehavioralHealth #ImmuneSystemDiseases #CardiometabolicDiseases #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/W8vQlDuLhSw

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Qilu Pharmaceutical

1 engagement

How We Help

Core Technology

Small molecule drugs, biosimilars, monoclonal antibodies, chemical drugs, and biological products, with strong capabilities in chemical synthesis, genetic engineering, and fermentation. Their R&D includes targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs).

Key Differentiators

Robust R&D capabilities with over 5,200 scientists across 6 R&D centers globally; Extensive manufacturing infrastructure with 11 domestic sites and USFDA/EDQM approval for sterile APIs; Global presence exporting to over 110 countries; Diverse product portfolio with over 350 marketed products; Strong commitment to international GMP standards.

Clinical Focus

Oncology, cerebrovascular & cardiovascular diseases, anti-infectives, psychological & neurological systems, respiratory system, ophthalmological diseases, nervous system diseases, endocrinology and metabolic disease, immune system diseases, and hemic and lymph diseases.

Target Customers

Global pharmaceutical companies (for APIs), hospitals, pharmacies, distributors, and agricultural sector (for crop protection products).

Product Stage

Mature

Company Info

Business Model: B2B (Business-to-Business)
Founded: 1958
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: en.qilu-pharma.com

Disease Areas

Cerebrovascular & Cardiovascular Diseases Anti-Infections Psychological & Neurological Systems Respiratory System Ophthalmological Diseases Nervous System Diseases Endocrinology and Metabolic Disease Hemic and Lymph Diseases Mental Health Immune system diseases Cardiometabolic Diseases Cancer & Oncology

Technologies

Small Molecule DrugsBiosimilarsMonoclonal AntibodiesChemical SynthesisGenetic EngineeringFermentationTargeted TherapiesAntibody-Drug Conjugates (ADCs)Immunotherapy

Clinical & IP

🔬

Clinical Validation

Achieved USFDA and EDQM approval for sterile APIs, indicating adherence to high international quality and regulatory standards. Known for many 'First-to-Launch' products in China.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Qilu Pharmaceutical?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.